Sugi Predict

Sugi Predict / Compounds / SCHEMBL2597799

SCHEMBL2597799

SCHEMBL2597799

CC(C)(C)OC(=O)N1CC(C(=O)O)CCC1c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 3/20 0.49
▸ NR1H2 P55055 3/20 0.47
▸ NR1H3 Q13133 3/20 0.47
▸ RORC P51449 2/20 0.43
▸ GPR119 Q8TDV5 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.41
▸ HTRA1 Q92743 1/20 0.41
▸ AKR1C3 P42330 1/20 0.40
▸ AKR1C1 Q04828 1/20 0.40
▸ ABCB1 P08183 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24366172 0.90 RIPK1 (0.47) RIPK1NR1H2NR1H3RORCGPR119
SCHEMBL19283243 0.88 NR1H2 (0.47) RIPK1NR1H2NR1H3RORCGPR119
SCHEMBL24365625 0.88 RIPK1 (0.45) RIPK1NR1H2NR1H3RORCGPR119
SCHEMBL24367704 0.88 NR1H2 (0.46) RIPK1NR1H2NR1H3RORCGPR119
SCHEMBL24366171 0.86 RIPK1 (0.45) RIPK1NR1H2NR1H3HSD17B10
SCHEMBL29477910 0.85 RIPK1 (0.50) RIPK1NR1H2NR1H3RORCGPR119
SCHEMBL24326437 0.85 RIPK1 (0.50) RIPK1NR1H2NR1H3RORCGPR119
SCHEMBL24367691 0.85 RIPK1 (0.50) RIPK1NR1H2NR1H3RORCGPR119
SCHEMBL24367702 0.85 RIPK1 (0.43) RIPK1NR1H2NR1H3RORCGPR119
SCHEMBL12668388 0.84 NR1H2 (0.56) RIPK1NR1H2NR1H3RORCGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
US-12304907-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-05-20 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-11999727-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-06-04 — — US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 — — CN disclosed
EP-4188920-A1 PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS Tango Therapeutics, Inc. (US) 2023-06-07 — — EP disclosed
US-20230113778-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-04-13 — — US disclosed
US-11492350-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2022-11-08 — — US disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 — — US disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 — — US disclosed
WO-2022026892-A1 PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS TANGO THERAPEUTICS, INC. (US) 2022-02-03 — — WO disclosed
US-9006268-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2015-04-14 — — US disclosed
US-9006268-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2015-04-14 — — US disclosed
US-20130090324-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME LLC 2013-04-11 — — US disclosed
US-20130090324-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME LLC 2013-04-11 — — US disclosed
EP-2571359-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-03-27 — — EP disclosed
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP 2013-03-07 — — US disclosed
WO-2011156246-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-12-15 — — WO disclosed
WO-2011146354-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999727-B2 Compounds and methods of use F12, C1R, ABCG2 RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP RIPK1 2764/4885NR1H2 2668/4885NR1H3 2970/4885
US-11492350-B2 Compounds and methods of use F12, C1R, ABCG2 RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885
US-20230113778-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885
US-20130090324-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP RIPK1 2764/4885NR1H2 2668/4885NR1H3 2970/4885
US-12304907-B2 Compounds and methods of use F12, C1R, ABCG2 RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 RIPK1 4792/4885NR1H2 76/4885NR1H3 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.